FDA Approves Xillix LIFE-Lung System
ROCKVILLE, Md-The FDA has given final approval to the Xillix LIFE-Lung Fluorescence Endoscopy System for use in detecting early lung cancer. Xillix Technologies Corp., of Richmond, British Columbia, plans to market the system worldwide in early 1997.
ROCKVILLE, MdThe FDA has given final approval to the Xillix LIFE-Lung Fluorescence Endoscopy System for use in detecting early lung cancer. Xillix Technologies Corp., of Richmond, British Columbia, plans to market the system worldwide in early 1997.
Articles in this issue
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clusters
AIDS Funding Increased for Fiscal '97
'Cancer Rates and Risks' Available
New Breast Cancer Patient Resource Is Available
Short-Term Metronidazole not Linked to Cancer
Various Capitation Models Are Available for Oncology Networks
NCI Urges full Disclosure of Cigarette Contents
Antifungal Resistance on the Increase
Fentanyl Patch Useful Alternative in Cancer Pain Patients
Analysis of Microvessel Density Predicts Extraprostatic Spread
Late Infection With Cytomegalovirus a Serious Problem in Bone Marrow Transplant Patients
FDA Panel Cancels HIV Drug Meeting
Klausner Cites Breast Cancer Progress in Jo Oberstar Lecture
Foundation Supports Legislation Backing Cancer Treatment Coverage
FDA Approves Xillix LIFE-Lung System
Recent Videos
Related Content
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
